Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapatinib + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Lapatinib + nab-paclitaxel is a combination therapy used primarily in the treatment of HER2-positive metastatic breast cancer. Lapatinib is an oral, reversible inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, which blocks signaling pathways involved in tumor cell proliferation and survival. Nab-paclitaxel is a formulation of the chemotherapy drug paclitaxel bound to albumin nanoparticles, enhancing its delivery to tumors and reducing solvent-related toxicity. Nab-paclitaxel disrupts microtubule function, inhibiting cell division and promoting apoptosis in cancer cells. This combination has been studied for efficacy and safety in patients with HER2-positive metastatic breast cancer who have received prior chemotherapy[1][3].
- Other names
- nanoparticle albumin-bound paclitaxelalbumin-bound paclitaxel
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lapatinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapatinib + nab-paclitaxel.